FDA To Review Vytorin Data: ENHANCEd Label To Follow?
Executive Summary
FDA expects to complete a review of data from the ENHANCE study for Merck and Schering-Plough's Vytorin within nine months, Office of New Drugs Director John Jenkins announced Jan. 25
You may also be interested in...
FDA Changes Its Mind On Vytorin; Ads Must Note “Efficacy Limitation”
One of the more interesting revelations from the House Energy and Commerce Committee's investigation into the ENHANCE trial is a document that may help explain why the Vytorin TV ads were pulled - and how FDA is handling questions about product efficacy in the current environment
FDA Changes Its Mind On Vytorin; Ads Must Note “Efficacy Limitation”
One of the more interesting revelations from the House Energy and Commerce Committee's investigation into the ENHANCE trial is a document that may help explain why the Vytorin TV ads were pulled - and how FDA is handling questions about product efficacy in the current environment
No Surprises From ENHANCE At ACC Mean Vytorin Hopes Hang On IMPROVE-IT
CHICAGO - With the full presentation of the results of the failed ENHANCE study at the American College of Cardiology annual meeting, a ringing endorsement for statin use and the results of IMPROVE-IT four years away, the door seems almost closed on Merck/Schering-Plough's Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin)